Envestnet Asset Management Inc. Grows Stock Holdings in ADMA Biologics Inc $ADMA

Envestnet Asset Management Inc. boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 108.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,229 shares of the biotechnology company’s stock after acquiring an additional 74,543 shares during the quarter. Envestnet Asset Management Inc. owned about 0.06% of ADMA Biologics worth $2,608,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. First Citizens Bank & Trust Co. raised its position in ADMA Biologics by 201.2% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 40,050 shares of the biotechnology company’s stock worth $729,000 after buying an additional 26,752 shares during the last quarter. D.A. Davidson & CO. raised its holdings in ADMA Biologics by 21.4% during the second quarter. D.A. Davidson & CO. now owns 30,060 shares of the biotechnology company’s stock worth $547,000 after purchasing an additional 5,300 shares in the last quarter. Cullen Frost Bankers Inc. lifted its position in ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,081 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in ADMA Biologics in the 2nd quarter valued at approximately $1,630,000. Finally, Huntleigh Advisors Inc. boosted its holdings in ADMA Biologics by 3.8% in the 2nd quarter. Huntleigh Advisors Inc. now owns 113,772 shares of the biotechnology company’s stock valued at $2,072,000 after purchasing an additional 4,156 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Stock Down 0.9%

ADMA stock opened at $15.56 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The company’s 50 day simple moving average is $15.24 and its 200-day simple moving average is $17.57. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The firm has a market capitalization of $3.71 billion, a PE ratio of 18.09 and a beta of 0.40.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. The firm had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.15 EPS. ADMA Biologics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.